Literature DB >> 4065194

Factors affecting the kinetics of two benzothiazine non-steroidal anti-inflammatory medicines, piroxicam and isoxicam.

I R Edwards, D G Ferry, A J Campbell.   

Abstract

The pharmacokinetics of isoxicam and piroxicam were compared in 12 young adults (less than 40 years) and 12 elderly subjects (greater than 65 years). After a single oral dose of 200 mg isoxicam or 20 mg piroxicam blood samples were taken for 168 h and the plasma drug concentrations determined by HPLC. The elimination half life of piroxicam for the adults was 57.1 +/- 16.4 h (mean +/- SD; harmonic mean 52.9 h) and for the elderly subjects was 57.8 +/- 22.1 h (harmonic mean 52.1 h). The corresponding values after isoxicam were 34.3 +/- 13.6 h (harmonic mean 31.6) for the adults and 39.1 +/- 22.7 h (harmonic mean 33.5) for the elderly subjects. Similarly no differences were noted in either the AUC0-infinity after piroxicam (adults 154.1 +/- 52.2 micrograms . h/ml, elderly 163.6 +/- 99.1 micrograms . h/ml) and isoxicam (adults 642.7 +/- 241.9 micrograms . h/ml, elderly 787.9 +/- 613.1 micrograms . h/ml) or the apparent oral clearance of piroxicam (adults 2.39 +/- 0.80 ml/min, elderly 2.51 +/- 0.90 ml/min) and isoxicam (adults 5.84 +/- 2.04 ml/min, elderly 5.59 +/- 2.12 ml/min). One adult and two elderly subjects exhibited slower elimination of both medicines than the remainder of each group. However determination of the oxidation phenotype using sparteine metabolism showed that this was not a likely determinant of the reduced clearance.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4065194     DOI: 10.1007/BF00607917

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  5 in total

1.  Pharmacokinetics of isoxicam in man following oral administration.

Authors:  E U Kölle; H Hengy; K O Vollmer
Journal:  Arzneimittelforschung       Date:  1983

2.  Benoxaprofen.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1982-08-14

3.  Pharmacokinetic analysis of concentration-time data obtained following administration of drugs that are recycled in the bile.

Authors:  W A Colburn
Journal:  J Pharm Sci       Date:  1984-03       Impact factor: 3.534

4.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

Review 5.  Piroxicam: a review of its pharmacological properties and therapeutic efficacy.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1981-09       Impact factor: 9.546

  5 in total
  4 in total

1.  The influence of cholestyramine on the elimination of tenoxicam and piroxicam.

Authors:  T W Guentert; R Defoin; H Mosberg
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Piroxicam and naproxen plasma concentrations in patients with osteoarthritis: relation to age, sex, efficacy and adverse events.

Authors:  H E Rugstad; O Hundal; I Holme; O B Herland; G Husby; K E Giercksky
Journal:  Clin Rheumatol       Date:  1986-09       Impact factor: 2.980

Review 3.  Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.

Authors:  K T Olkkola; A V Brunetto; M J Mattila
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

4.  The pharmacokinetics of piroxicam in elderly persons with and without renal impairment.

Authors:  A C Rudy; N L Figueroa; S D Hall; D C Brater
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.